Arrowhead Pharmaceuticals (NASDAQ:ARWR) posted its earnings results on Monday. The biotechnology company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.65), MarketWatch Earnings reports. Arrowhead Pharmaceuticals had a negative return on equity of 28.00% and a negative net margin of 116.97%. During the same quarter last year, the business posted ($0.48) earnings per share.
ARWR traded up $0.36 on Wednesday, hitting $71.25. The company’s stock had a trading volume of 1,609 shares, compared to its average volume of 742,274. The company’s 50 day simple moving average is $66.91 and its 200-day simple moving average is $69.40. The firm has a market cap of $7.43 billion, a P/E ratio of -57.63 and a beta of 1.14. Arrowhead Pharmaceuticals has a 12 month low of $56.05 and a 12 month high of $93.66.
In other news, Director Adeoye Y. Olukotun sold 5,000 shares of the firm’s stock in a transaction on Monday, September 13th. The shares were sold at an average price of $63.76, for a total transaction of $318,800.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Martin Javier San sold 19,500 shares of the firm’s stock in a transaction on Friday, November 19th. The shares were sold at an average price of $69.31, for a total transaction of $1,351,545.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 89,500 shares of company stock valued at $5,945,295. 3.50% of the stock is owned by insiders.
A number of equities research analysts have issued reports on the stock. SVB Leerink upped their price objective on shares of Arrowhead Pharmaceuticals from $44.00 to $45.00 and gave the stock a “market perform” rating in a research report on Tuesday. Chardan Capital reduced their price objective on shares of Arrowhead Pharmaceuticals from $97.00 to $94.00 and set a “buy” rating for the company in a research report on Friday, August 6th. TheStreet raised shares of Arrowhead Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, November 4th. Finally, HC Wainwright increased their target price on shares of Arrowhead Pharmaceuticals from $95.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, August 10th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $88.09.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R.
Featured Article: What is the CAC 40 Index
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.